NCT04210375 - Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

June 8, 2023

Study Completion Date

July 7, 2023

Conditions

Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

JK07

Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1

DRUG

Matching Placebo

Vehicle control

Trial Locations (7)

44195

Cleveland Clinic, Cleveland

75390

University of Texas Southwestern, Dallas

77030

Houston Methodist Hospital, Houston

94305

Stanford University Medical Center, Stanford

97239

Oregon Health Science University Hospital, Portland

85724-5039

University of Arizona College of Medicine, Tucson

02114-2696

Harvard Medical School/ Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Salubris Biotherapeutics Inc

INDUSTRY